These Numbers Show Favorable Signs for Novo Nordisk ADR (NVO)

Novo Nordisk ADR (NYSE: NVO) is 17.16% higher on its value in year-to-date trading and has touched a low of $67.66 and a high of $119.67 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NVO stock was last observed hovering at around $118.39 in the last trading session, with the day’s gains setting it 2.81%.

Currently trading at $121.20, the stock is 9.86% and 15.39% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.29 million and changing 2.37% at the moment leaves the stock 30.61% off its SMA200. NVO registered 73.66% gain for a year compared to 6-month gain of 33.12%. The firm has a 50-day simple moving average (SMA 50) of $2.31 and a 200-day simple moving average (SMA200) of $4.67.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a 11.53% loss in the last 1 month and extending the period to 3 months gives it a 19.10%, and is 6.60% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.79% over the week and 1.63% over the month.

Novo Nordisk ADR (NVO) has around Aug 18 2023 employees, a market worth around $410.07B and $33.70B in sales. Current P/E ratio is 44.87 and Fwd P/E is 30.38. Profit margin for the company is 36.04%. Distance from 52-week low is 79.13% and 1.28% from its 52-week high. The company has generated returns on investments over the last 12 months (64.47%).

Novo Nordisk ADR quarterly earnings per share for the current quarter are estimated at $0.79 with sales reaching $9.6B over the same period.The EPS is expected to grow by 22.30% this year, but quarterly earnings will post 22.90% year-over-year. Quarterly sales are estimated to grow 26.60% in year-over-year returns.

Novo Nordisk ADR (NVO) Top Institutional Holders

1,581 institutions hold shares in Novo Nordisk ADR (NVO), with institutional investors hold 9.16% of the company’s shares. The shares outstanding are 3.38B, and float is at 3.38B with Short Float at 0.22%. Institutions hold 9.16% of the Float.

The top institutional shareholder in the company is Jennison Associates LLC with over 23.38 million shares valued at $1.89 billion. The investor’s holdings represent 0.68% of the NVO Shares outstanding. As of Jun 29, 2023, the second largest holder is Renaissance Technologies, LLC with 18.74 million shares valued at $1.52 billion to account for 0.55% of the shares outstanding. The other top investors are Fisher Asset Management, LLC which holds 15.24 million shares representing 0.44% and valued at over $1.23 billion, while Bank of America Corporation holds 0.36% of the shares totaling 12.46 million with a market value of $1.01 billion.

Novo Nordisk ADR (NVO): Who are the competitors?

The company’s main competitors (and peers) include Eli Lilly & Co. (LLY) that is trading 111.23% up over the past 12 months. Sanofi ADR (SNY) that is -1.90% lower over the same period.